Chimeric antigen receptor T-cell (CAR-T) therapy has decisively outperformed conventional salvage chemotherapy in a pivotal Phase 3 trial for patients with relapsed or refractory large B-cell lymphoma (LBCL), researchers reported this week at the American Society of Hematology annual meeting.
Trial Results
The ZUMA-7 trial enrolled 359 patients with LBCL that relapsed within 12 months of first-line chemoimmunotherapy — historically among the hardest-to-treat patient populations in hematologic oncology. Patients were randomized to receive axicabtagene ciloleucel (axi-cel) CAR-T therapy or standard-of-care chemotherapy followed by autologous stem cell transplantation in responders.
Key findings at 5-year follow-up:
- Complete response rate: 73% (CAR-T) vs. 33% (SOC chemo)
- Event-free survival at 4 years: 41.8% vs. 24.4%
- Overall survival at 5 years: 52.8% vs. 33.1%
- Median overall survival: Not reached (CAR-T) vs. 31.1 months (chemo)
“A 5-year overall survival of 52% — in a disease that two years ago had a median survival under 3 years — is extraordinary. We are curing patients who previously had no good options.”
— Dr. Frederick Locke, Moffitt Cancer Center, lead investigator
Understanding the Technology
CAR-T therapy works by extracting a patient’s own T cells, genetically engineering them in the laboratory to express chimeric antigen receptors that recognize CD19 — a protein on the surface of B-cell lymphoma cells — then infusing the modified cells back into the patient. The engineered T cells seek out and destroy cancer cells with high precision.
Managing Toxicity
The therapy’s efficacy comes with notable toxicity. Cytokine release syndrome (CRS) occurred in 92% of CAR-T patients (6% Grade 3+), and immune effector cell-associated neurotoxicity syndrome (ICANS) in 60% (21% Grade 3+). All serious toxicities resolved with standard management protocols including tocilizumab and corticosteroids.
Expanding Access
CAR-T therapy currently requires specialized treatment centers with intensive care capabilities. The cost of a single infusion ranges from $400,000 to $500,000 — a barrier the authors acknowledge must be addressed. Several manufacturers are pursuing off-the-shelf allogeneic CAR-T products that could dramatically reduce cost and manufacturing time.
The FDA approved the second-line indication for axi-cel in April 2022; these 5-year data substantially strengthen the evidence base for moving CAR-T therapy earlier in the treatment algorithm.
Leave a Reply